Evidence map›Paper›PMID 40970911›Full record

ReviewPharmacogenomics

How to implement pre-emptive pharmacogenetic testing in the acute hospital setting.

John Henry McDermott, Ali Shoaib, Jessica Keen, Charlotte Skitterall, Videha Sharma, William Gerard Newman

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacogenomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

John Henry McDermottDivision of Evolution, Infection and Genomics, School of Biological Sciences, University of Manchester, Manchester, UK.ORCID 0000-0002-5220-8837
Ali ShoaibPharmacy Department, Manchester University NHS Foundation Trust, Manchester, UK.
Jessica KeenDivision of Evolution, Infection and Genomics, School of Biological Sciences, University of Manchester, Manchester, UK.ORCID 0009-0009-7708-8534
Charlotte SkitterallPharmacy Department, Manchester University NHS Foundation Trust, Manchester, UK.ORCID 0009-0001-4017-8343
Videha SharmaCentre for Health Informatics, Division of Informatics, Imaging and Data Science, University of Manchester, Manchester, UK.ORCID 0000-0001-7640-1239
William Gerard NewmanDivision of Evolution, Infection and Genomics, School of Biological Sciences, University of Manchester, Manchester, UK.ORCID 0000-0002-6382-4678

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Your hospital has decided to introduce a pharmacogenomics program. What do you need to do to realize this ambition? In this paper, we set out the elements that should be considered, including the team and resources required to establish a sustainable program. This will draw on experience from successful global pharmacogenomic programs and will highlight key interdependencies, opportunities and challenges.

Indexed as

HospitalsPharmacogeneticsPharmacogenomic TestingHumansPrecision Medicineacute carehospitalimplementationPharmacogenomicspoint of carepreemptive

Identifiers

PMID40970911
PMCPMC12520090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.